Targeted cancer drug trial halted after testing in 19 patients
NCT ID NCT06478862
Summary
This study tested an experimental drug called Promitil for people with advanced ovarian or pancreatic cancer that had specific genetic mutations and had worsened after initial treatment. The trial aimed to see if this new formulation could better control cancer growth while being safer than similar existing drugs. The study was terminated early and only enrolled 19 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rambam Health Care Campus
Haifa, Israel
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shamir Medical Center (Asaf Harofeh)
Ẕerifin, 70300, Israel
-
Soroka Medical Center
Beersheba, Israel
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Wolfson Medica Center
Holon, 5822012, Israel
Conditions
Explore the condition pages connected to this study.